+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Osteoarthritis and Osteoarthritis Pain

  • ID: 4775098
  • Report
  • 61 pages
  • Datamonitor Healthcare
1 of 2
This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The author estimates that in 2017, there were 308.9 million prevalent cases of osteoarthritis (knee or hip) in adults aged 30 years and older worldwide, and forecasts that number to increase to 358.4 million prevalent cases by 2026.
  • The global prevalence of osteoarthritis is estimated to be 8.2%. The approved drugs in the osteoarthritis space focus on a wide variety of targets. The majority of these therapies are administered via the oral route, with the remainder being topical, intraarticular, and transdermal formulations.
  • The majority of industry-sponsored drugs in active clinical development for osteoarthritis are in Phase II. Therapies in development for osteoarthritis focus on a wide variety of targets. The majority of pipeline drugs are administered via the intraarticular route.
  • High-impact upcoming events for drugs in the osteoarthritis space comprise topline Phase IIb and Phase III trial results for AmnioFix, and topline Phase III trial results for CNTX-4975 and fasinumab.
  • The overall likelihood of approval of a Phase I osteoarthritis and osteoarthritis pain asset is 10.9%, and the average probability a drug advances from Phase III is 50%. Drugs, on average, take 11.8 years from Phase I to approval in the osteoarthritis and osteoarthritis pain space, as well as the overall rheumatology (non autoimmune) space.
  • There have been 39 licensing and asset acquisition deals involving osteoarthritis drugs during 2014–19. The $600m multi-year agreement signed in November 2018 between Mundipharma and Kolon Life Sciences, for the development, marketing, and distribution of Invossa to medical professionals and hospitals in Japan, was the largest deal during the period.
  • The distribution of clinical trials across Phase I–IV indicates that the majority of trials for osteoarthritis have been in the early and mid-phases of development, with 57% of trials in Phase I–II, and 43% in Phase III–IV.
  • The US has a substantial lead in the number of osteoarthritis clinical trials globally. The UK leads the major EU markets, while South Korea has the top spot in Asia.
  • Clinical trial activity in the osteoarthritis space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for osteoarthritis, with 109 trials.
  • Pfizer leads industry sponsors with the highest overall number of clinical trials for osteoarthritis
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
  • Non-pharmacological treatment
  • Pharmacological treatment
  • Surgery
EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • Tanezumab for Osteoarthritis and Osteoarthritis Pain (April 18, 2019)
  • Tanezumab for Osteoarthritis and Osteoarthritis Pain (January 29, 2019)
  • Zilosul for Osteoarthritis and Osteoarthritis Pain (December 18, 2018)
  • Lorecivivint for Osteoarthritis and Osteoarthritis Pain (October 23, 2018)
  • Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 16, 2018)
  • Ampion for Osteoarthritis and Osteoarthritis Pain (August 7, 2018)
  • Tanezumab for Osteoarthritis and Osteoarthritis Pain (July 18, 2018)
  • Cingal for Osteoarthritis and Osteoarthritis Pain (June 19, 2018)
  • Invossa for Osteoarthritis and Osteoarthritis Pain (February 27, 2018)
  • Ampion for Osteoarthritis and Osteoarthritis Pain (December 14, 2017)
KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
  • Global Device Approvals Snapshot: 4–10 June 2019
  • Invossa Approval Revoked As Korea Confirms False Data Submission
  • Invossa Gene Therapy Controversy Grows As Government, Patients Take Action
  • Korea Suspends First Approved Gene Therapy Pending Component Discrepancy Probe
  • Global Device Approvals Snapshot For March 26–April 1, 2019
  • Nature Cell Keeps Hopes Up For JointStem Despite Conditional Approval Rejection
PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • Kolon Bounces Back From Failed Japan Invossa Deal With Bigger Mundipharma Alliance
PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
BIBLIOGRAPHY
  • Prescription information
APPENDIX

LIST OF FIGURES
Figure 1: Trends in prevalent cases of osteoarthritis (knee or hip), 2017–26
Figure 2: Overview of pipeline drugs for osteoarthritis in the US
Figure 3: Pipeline drugs for osteoarthritis, by company
Figure 4: Pipeline drugs for osteoarthritis, by drug type
Figure 5: Pipeline drugs for osteoarthritis, by classification
Figure 6: Tanezumab for Osteoarthritis and Osteoarthritis Pain (April 18, 2019): Phase III - OA Safety Study (vs. NSAIDs)
Figure 7: Tanezumab for Osteoarthritis and Osteoarthritis Pain (January 29, 2019): Phase III - OA of Hip or Knee (6 Months EU Study)
Figure 8: Zilosul for Osteoarthritis and Osteoarthritis Pain (December 18, 2018): Phase IIb - PARA_005 (Knee Pain from Osteoarthritis and BMELs)
Figure 9: Lorecivivint for Osteoarthritis and Osteoarthritis Pain (October 23, 2018): Phase IIb - SM04690-OA-04
Figure 10: Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 16, 2018): Phase III - FACT LTS & OA
Figure 11: Tanezumab for Osteoarthritis and Osteoarthritis Pain (July 18, 2018): Phase III - A4091056 (Severe OA of the Hip or Knee)
Figure 12: Cingal for Osteoarthritis and Osteoarthritis Pain (June 19, 2018): Phase III - CINGAL 16-02 (EU)
Figure 13: Invossa for Osteoarthritis and Osteoarthritis Pain (February 27, 2018): Phase III - KS-TGC-01-3 (Korea)
Figure 14: Ampion for Osteoarthritis and Osteoarthritis Pain (December 14, 2017): Phase III - AP-003-C
Figure 15: Key upcoming events in osteoarthritis
Figure 16: Probability of success in the osteoarthritis pipeline
Figure 17: Licensing and asset acquisition deals in osteoarthritis, 2014-19
Figure 18: Parent patents in osteoarthritis
Figure 19: Clinical trials in osteoarthritis
Figure 20: Top 10 drugs for clinical trials in osteoarthritis
Figure 21: Top 10 companies for clinical trials in osteoarthritis
Figure 22: Trial locations in osteoarthritis
Figure 23: Osteoarthritis trials status
Figure 24: Osteoarthritis trials sponsors, by phase

LIST OF TABLES
Table 1: Prevalent cases of osteoarthritis (knee or hip), 2017–26
Table 2: Marketed drugs for osteoarthritis
Table 3: Pipeline drugs for osteoarthritis in the US
Table 4: Tanezumab for Osteoarthritis and Osteoarthritis Pain (April 18, 2019)
Table 5: Tanezumab for Osteoarthritis and Osteoarthritis Pain (January 29, 2019)
Table 6: Zilosul for Osteoarthritis and Osteoarthritis Pain (December 18, 2018)
Table 7: Lorecivivint for Osteoarthritis and Osteoarthritis Pain (October 23, 2018)
Table 8: Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 16, 2018)
Table 9: Ampion for Osteoarthritis and Osteoarthritis Pain (August 7, 2018)
Table 10: Tanezumab for Osteoarthritis and Osteoarthritis Pain (July 18, 2018)
Table 11: Cingal for Osteoarthritis and Osteoarthritis Pain (June 19, 2018)
Table 12: Invossa for Osteoarthritis and Osteoarthritis Pain (February 27, 2018)
Table 13: Ampion for Osteoarthritis and Osteoarthritis Pain (December 14, 2017)
Table 14: Historical global sales, by drug ($m), 2014–18
Table 15: Forecasted global sales, by drug ($m), 2019–23
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll